EP Patent

EP3455209A1 — Crystalline forms of apremilast

Assigned to Zaklady Farmaceutyczne Polpharma SA · Expires 2019-03-20 · 7y expired

What this patent protects

The invention particularly relates to crystailine (solid) forms of N-[2-[(1S)-1-(3-ethoxy-4- methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1 H-isoindol-4-yl]acetamide), i.e. Form N, Form M, Form O and Form P. It also refers to a pharmaceutical composition or dosag…

USPTO Abstract

The invention particularly relates to crystailine (solid) forms of N-[2-[(1S)-1-(3-ethoxy-4- methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1 H-isoindol-4-yl]acetamide), i.e. Form N, Form M, Form O and Form P. It also refers to a pharmaceutical composition or dosage form comprising said crystalline forms. The invention also concerns said pharmaceuticai composition or dosage form for use in a method of treating a disease or disorder defined in the claims. Finally, the invention pertains to the use of said novel crystalline forms for the preparation of a pharmaceutical composition or dosage form.

Drugs covered by this patent

Patent Metadata

Patent number
EP3455209A1
Jurisdiction
EP
Classification
—
Expires
2019-03-20
Drug substance claim
No
Drug product claim
No
Assignee
Zaklady Farmaceutyczne Polpharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.